Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Coronavirus Stock CureVac Crushed It on Thursday

By Eric Volkman - Jan 7, 2021 at 6:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus vaccine developer announced a new partnership with a major player on the global pharmaceutical scene.

What happened

Shares of CureVac ( CVAC 0.18% ) surged almost 17% higher on Thursday after the company announced it found a well-capitalized and famous partner to help get its coronavirus vaccine to market.

So what

CureVac said it has signed a collaboration and services agreement with global pharmaceutical powerhouse Bayer ( BAYR.Y -2.03% ) regarding the former's coronavirus vaccine candidate, CVnCoV.

Gloved hands holding a vial of medicine.

Image source: Getty Images.

CureVac said that under the agreement, the financial terms of which were not made public, "CureVac will be the Marketing Authorization Holder for the product, while Bayer will support CureVac with country operations within the European Union (EU) and selected additional markets." Bayer also holds options to become the marketing authorization holder outside of Europe, its partner added.

According to the biotech, this deal positions it to supply "hundreds of millions" of doses of the vaccine globally. Last month, CVnCoV entered phase 3 clinical testing. Since it's still under evaluation, it hasn't been approved for use anywhere.

Now what

It's hard to judge accurately how this might impact CureVac's fundamentals, since we don't know the financial framework of the deal. And it nearly goes without saying that there's no guarantee that CVnCoV will be successful in its current round of testing, not to mention win regulatory approval.

That said, no matter the terms of the company's partnership with Bayer, it will be a real boon for CVnCoV to have such a powerful international partner if it tests well and ultimately goes to market. Today's share-price pop was justified on that basis.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CureVac N.V. Stock Quote
CureVac N.V.
$44.03 (0.18%) $0.08
Bayer Stock Quote
$12.53 (-2.03%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.